Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2013-001225-11-FI
EUCTR2013-001225-11-FI
Active, Not Recruiting
N/A

Quantitative myocardial perfusion response to adenosine and regadenoson in patients with suspected coronary artery disease - RegWater

Turku University Hospital0 sites30 target enrollmentMay 13, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsAdenocorRapiscan

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Turku University Hospital
Enrollment
30
Status
Active, Not Recruiting
Last Updated
12 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 13, 2013
End Date
TBD
Last Updated
12 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •One of the following:
  • •Suspected CAD and referred for cardiac PET perfusion imaging based on clinical indications
  • •Known CAD and referred for cardiac PET perfusion imaging based on clinical indications
  • •Patients have been or are referred for coronary angiography, either noninvasive or invasive
  • •Informed consent from the patient
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 8
  • •F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • •Continuing, uncontrolled unstable angina symptoms or urgent CABG after invasive coronary angiography
  • •ST\-elevation myocardial infarction (STEMI)
  • •EF \< 40% or diagnosis of cardiomyopathy
  • •Prior coronary artery bypass grafting (CABG)
  • •Haemophilia, Von Willebrand's disease or other coagulation disorder
  • •Severe pulmonary disease
  • •Symptomatic asthma
  • •Severe valvular disease
  • •Uncontrolled hypertension (\>180/110 mmHg)
  • •Moderate to severe renal failure

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
N/A
Myocardial perfusion with an intravascular contrast agentCoronary artery diseaseCirculatory SystemChronic ischaemic heart disease
ISRCTN53688797King's College London (UK)156
Active, Not Recruiting
N/A
Quantitative Assessment of Myocardial Perfusion with Magnetic Resonance Using an Intravascular Contrast AgentIschemic cardiomyopathy, with inducible ischemia and clinical indication to cardiac revascularizationMedDRA version: 9.1Level: LLTClassification code 10055217Term: Ischemic cardiomyopathy
EUCTR2008-004895-39-GBKing's College London
Completed
N/A
Assessment of Myocardial Perfusion Linked to Infarction and Fibrosis Explored with DSCT.
JPRN-UMIN000016353Department of Radiology,Mie University Graduate School of Medicine200
Active, Not Recruiting
Phase 1
HYPER-trial Hyperemic mYocardial Perfusion by adEnosine at diffeRent dosesChronic coronary syndromeMedDRA version: 20.0Level: LLTClassification code: 10008937Term: Chronic ischemic heart disease unspecified Class: 10007541MedDRA version: 20.0Level: LLTClassification code: 10055218Term: Ischemic heart disease Class: 10007541Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
CTIS2023-505248-20-00Region Skane180
Completed
Phase 4
Adrenaline for the Treatment of No-Reflow in Normotensive PatientsAcute Coronary SyndromeNo-Reflow PhenomenonNormotensive
NCT04699110National Institute of Cardiovascular Diseases, Pakistan201